Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms

This technology identifies twenty five (25) new alternatively spliced transcripts of the BORIS gene. The transcripts lead to the expression of seventeen different protein isoforms with variable N- and C-termini encoded by BORIS gene locus. Differential expression levels of BORIS isoforms were observed in different cancers. While some BORIS alternative splice variants were expressed at different levels in all types of cancers, other expressed forms are specific to particular cancer(s).

Potential Commercial Applications:		Competitive Advantages:
Simple, rapid, RT-PCR based diagnostic test to detect BORIS isoforms in cancer patients. Profiling of BORIS splice variants can be useful as a diagnostic tool for the detection of cancers. BORIS can be a therapeutic target antigen for immunotherapeutic and/or siRNA based treatments for cancer. BORIS can be used in combination with other established immunogens for immunotherapeutic treatment of several cancers.

Development Stage:
The technology is currently in the pre-clinical stage of development.

Inventors:

Victor Lobanenkov (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,206,933 issued 2012-06-26
U.S. Pat: 8,440,415 issued 2013-05-14
US Application No. 12/439,063
US Application No. 13/478,779

Collaboration Opportunity:
The NIAID Laboratory of Immunopathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods of cancer diagnostics and treatment based on detection of BORIS isoforms. Please contact Cecilia Pazman at pazmance@niaid.nih.gov or (301) 451-3526 for more information.


Licensing Contact:
Christopher Kornak, J.D.
Email: chris.kornak@nih.gov
Phone: 240-627-3705

OTT Reference No: E-117-2006-0
Updated: Jun 1, 2007